|Bid||0.5411 x 1200|
|Ask||0.5600 x 1000|
|Day's range||0.5351 - 0.5799|
|52-week range||0.4280 - 8.4750|
|Beta (5Y monthly)||1.16|
|PE ratio (TTM)||N/A|
|Earnings date||25 Mar 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Molecular Data, Inc. ("Molecular Data" or the "Company") (NASDAQ: MKD), a technology-driven platform in China, announced that it had received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that to date, it has not regained compliance with the Rule 5250(c)(1).
Molecular Data, Inc. ("Molecular Data" or the "Company") (NASDAQ: MKD), a technology-driven platform in China, announced today that on May 25, 2021, it had received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that its minimum closing bid price per share for its ordinary shares had fallen below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). On Novemb
Molecular Data Inc. (NASDAQ: MKD) (the "Company") announced today a ratio change on its American Depositary Shares ("ADS") from the current one (1) ADS representing three (3) Class A ordinary shares to the new ratio of one (1) ADS representing forty-five (45) Class A ordinary shares (the "Ratio Change"). The effective date of the Ratio Change is expected to be May 23, 2022.